Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2002-12-12
2004-12-28
Pryor, Alton N. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
C552S653000
Reexamination Certificate
active
06835723
ABSTRACT:
BACKGROUND OF THE INVENTION
The present invention relates to purification of organic compounds, and more particularly to the purification of 2-methylene-19-nor-20(S)-1&agr;-hydroxy-bis-homo-pregnacalciferol (referred to herein as 2MBP and/or 2-MbisP) by preparing it in crystalline form.
Purification of organic compounds, especially those designated for pharmaceutical use, is of considerable importance for chemists synthesizing such compounds. Preparation of the compound usually requires many synthetic steps and, therefore, the final product can be contaminated not only with side-products derived from the last synthetic step of the procedure but also with compounds that were formed in previous steps. Even chromatographic purification, which is a very efficient but relatively time-consuming process, does not usually provide compounds which are sufficiently pure to be used as drugs.
Depending on the method used to synthesize 1&agr;-hydroxyvitamin D compounds, different minor undesirable compounds can accompany the final product. Thus, for example, if direct C-1 hydroxylation of 5,6-trans geometric isomer of vitamin D is performed, followed by SeO
2
/NMO oxidation and photochemical irradiation [see Andrews et al.,
J. Org. Chem.
51, 1635 (1986); Calverley et al.,
Tetrahedron
43, 4609 (1987); Choudry et al.,
J. Org. Chem.
58, 1496 (1993)], the final 1&agr;-hydroxyvitamin D product can be contaminated with 1&bgr;-hydroxy- as well as 5,6-trans isomers. If the method consists of C-1 allylic oxidation of the 4-phenyl-1,2,4-triazoline-3,5-dione adduct of the previtamin D compound, followed by cycloreversion of the modified adduct under basic conditions [Nevinckx et al.,
Tetrahedron
47, 9419 (1991); Vanmaele et al.,
Tetrahedron
41, 141 (1985) and 40, 1179 (1991); Vanmaele et al.,
Tetrahedron Lett.
23, 995 (1982)], one can expect that the desired 1&agr;-hydroxyvitamin can be contaminated with the previtamin 5(10),6,8-triene and 1&bgr;-hydroxy isomer. One of the most useful C-1 hydroxylation methods, of very broad scope and numerous applications, is the experimentally simple procedure elaborated by Paaren et al. [see
J. Org. Chem.
45, 3253 (1980) and
Proc. Natl. Acad. Sci. U.S.A.
75, 2080 (1978)]. This method consists of allylic oxidation of 3,5-cyclovitamin D derivatives, readily obtained from the buffered solvolysis of vitamin D tosylates, with SeO
2
/t-BuOOH and subsequent acid-catalyzed cycloreversion to the desired 1&agr;-hydroxy compounds. Taking into account this synthetic path it is reasonable to assume that the final product can be contaminated with 1&agr;-hydroxy epimer, 5,6-trans isomer and the previtamin D form. 1&agr;-hydroxyvitamin D
4
is another undesirable contaminant found in 1&agr;-hydroxyvitamin D compounds synthesized from vitamin D
2
or from ergosterol. 1&agr;-hydroxyvitamin D
4
results from C-1 oxidation of vitamin D
4
, which in turn is derived from contamination of the commercial ergosterol material. Typically, the final product may contain up to about 1.5% by weight 1&agr;-hydroxyvitamin D
4
. Thus, a purification technique that would eliminate or substantially reduce the amount of 1&agr;-hydroxyvitamin D
4
in the final product to less than about 01.-0.2% would be highly desirable.
The vitamin D conjugated triene system is not only heat- and light-sensitive but it is also prone to oxidation, leading to the complex mixture of very polar compounds. Oxidation usually happens when a vitamin D compound has been stored for a prolonged time. Other types of processes that can lead to a partial decomposition of vitamin D compounds consist of the some water-elimination reactions; their driving force is allylic (1&agr;-) and homoallylic (3&bgr;-) position of the hydroxy groups. The presence of such above-mentioned oxidation and elimination products can be easily detected by thin-layer chromatography. Thus, for example, using precoated aluminum silica sheets [with UV indicator; from EM Science (Cherry Hill, N.J.)] and solvent system hexane-ethyl acetate (4:6), the spot of 1&agr;-OH-D
2
(R
f
0.27) and its elimination products (R
f
's ca. 0.7-0.9) are visible in ultraviolet light. Also, after spraying with sulfuric acid and heating, an additional spot can be visualized (R
f
0), derived from oxidation products.
Usually, all 1&agr;-hydroxylation procedures require at least one chromatographic purification. However, even chromatographically purified 1&agr;-hydroxyvitamin D compounds, although showing consistent spectroscopic data, suggesting homogeneity, does not meet the purity criteria required for therapeutic agents that can be orally, parenterally or transdermally administered. Therefore, it was evident that a suitable method of purification of 2MBP is required.
SUMMARY OF THE INVENTION
The present invention relates to a method of purifying 2MBP by means of crystallization to obtain 2MBP in crystalline form. The solvent plays a crucial role in the crystallization process, and is typically an individual liquid substance or a suitable mixture of different liquids. For crystallizing 2MBP, the most appropriate solvent and/or solvent system is characterized by the following factors:
(1) low toxicity;
(2) low boiling point;
(3) significant dependence of solubility properties with regard to temperature (condition necessary for providing satisfactory crystallization yield); and
(4) relatively low cost.
It was found that highly apolar solvents (e.g. hydrocarbons) were not suitable due to the low solubility of 2MBP in them. Quite the reverse situation occurred in highly polar solvent media (e.g. alcohols), in which 2MBP showed too high solubility. Therefore, it was concluded that for the successful crystallization of 2MBP, a solvent of medium polarity is required. Interestingly, hexane, so frequently used for crystallization purposes, was found less suitable for crystallization of 2MBP. However, it was found that an individual solvent, namely acetone, was most useful for the crystallization of 2MBP. In addition, it is believed that solvent systems utilizing ethyl acetate, or isopropanol, or chloroform, or dichloromethane, or diethyl ether would also perform well. These solvents are all very easy to remove by evaporation or other well known methods. In all cases the crystallization process occurred easily and efficiently; and the precipitated crystals were sufficiently large to assure their recovery by filtration.
REFERENCES:
patent: 5936133 (1999-08-01), DeLuca et al.
Clagett-Dame Margaret
DeLuca Hector F.
Gowlugari Sumithra
Grzywacz Pawel
Holden Hazel M.
Andrus Sceales Starke & Sawall LLP
Pryor Alton N.
Wisconsin Alumni Research Foundation
LandOfFree
2-methylene-19-nor-20(S)-1&agr;-hydroxy-bis-homo-pregnacalci... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 2-methylene-19-nor-20(S)-1&agr;-hydroxy-bis-homo-pregnacalci..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 2-methylene-19-nor-20(S)-1&agr;-hydroxy-bis-homo-pregnacalci... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3334955